Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen

β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that t...

Full description

Bibliographic Details
Main Authors: Kazuko Kobayashi, Makoto Kishi, Tatsuya Atsumi, Maria L. Bertolaccini, Hirofumi Makino, Nobuo Sakairi, Itaru Yamamoto, Tatsuji Yasuda, Munther A. Khamashta, Graham R.V. Hughes, Takao Koike, Dennis R. Voelker, Eiji Matsuura
Format: Article
Language:English
Published: Elsevier 2003-04-01
Series:Journal of Lipid Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520311615
id doaj-0164a5f6c85e4caebf18c4d8e4410e83
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Kazuko Kobayashi
Makoto Kishi
Tatsuya Atsumi
Maria L. Bertolaccini
Hirofumi Makino
Nobuo Sakairi
Itaru Yamamoto
Tatsuji Yasuda
Munther A. Khamashta
Graham R.V. Hughes
Takao Koike
Dennis R. Voelker
Eiji Matsuura
spellingShingle Kazuko Kobayashi
Makoto Kishi
Tatsuya Atsumi
Maria L. Bertolaccini
Hirofumi Makino
Nobuo Sakairi
Itaru Yamamoto
Tatsuji Yasuda
Munther A. Khamashta
Graham R.V. Hughes
Takao Koike
Dennis R. Voelker
Eiji Matsuura
Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
Journal of Lipid Research
antiphospholipid syndrome
arterial thrombosis
autoantibody
author_facet Kazuko Kobayashi
Makoto Kishi
Tatsuya Atsumi
Maria L. Bertolaccini
Hirofumi Makino
Nobuo Sakairi
Itaru Yamamoto
Tatsuji Yasuda
Munther A. Khamashta
Graham R.V. Hughes
Takao Koike
Dennis R. Voelker
Eiji Matsuura
author_sort Kazuko Kobayashi
title Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
title_short Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
title_full Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
title_fullStr Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
title_full_unstemmed Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen
title_sort circulating oxidized ldl forms complexes with β2-glycoprotein i: implication as an atherogenic autoantigen
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 2003-04-01
description β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that the β2-GPI ligands are ω-carboxylated 7-ketocholesteryl esters. In the present study, we demonstrate that oxLDL forms stable and nondissociable complexes with β2-GPI in serum, and that high serum levels of the complexes are associated with arterial thrombosis in APS. A conjugated ketone function at the 7-position of cholesterol as well as the ω-carboxyl function of the β2-GPI ligands was necessary for β2-GPI binding. The ligand-mediated noncovalent interaction of β2-GPI and oxLDL undergoes a temperature- and time-dependent conversion to much more stable but readily dissociable complexes in vitro at neutral pH. In contrast, stable and nondissociable β2-GPI-oxLDL complexes were frequently detected in sera from patients with APS and/or systemic lupus erythematodes. Both the presence of β2-GPI-oxLDL complexes and IgG Abs recognizing these complexes were strongly associated with arterial thrombosis. Further, these same Abs correlated with IgG immune complexes containing β2-GPI or LDL.Thus, the β2-GPI-oxLDL complexes acting as an autoantigen are closely associated with autoimmune-mediated atherogenesis.
topic antiphospholipid syndrome
arterial thrombosis
autoantibody
url http://www.sciencedirect.com/science/article/pii/S0022227520311615
work_keys_str_mv AT kazukokobayashi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT makotokishi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT tatsuyaatsumi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT marialbertolaccini circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT hirofumimakino circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT nobuosakairi circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT itaruyamamoto circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT tatsujiyasuda circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT muntherakhamashta circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT grahamrvhughes circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT takaokoike circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT dennisrvoelker circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
AT eijimatsuura circulatingoxidizedldlformscomplexeswithb2glycoproteiniimplicationasanatherogenicautoantigen
_version_ 1721506977291436032
spelling doaj-0164a5f6c85e4caebf18c4d8e4410e832021-04-27T04:39:07ZengElsevierJournal of Lipid Research0022-22752003-04-01444716726Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigenKazuko Kobayashi0Makoto Kishi1Tatsuya Atsumi2Maria L. Bertolaccini3Hirofumi Makino4Nobuo Sakairi5Itaru Yamamoto6Tatsuji Yasuda7Munther A. Khamashta8Graham R.V. Hughes9Takao Koike10Dennis R. Voelker11Eiji Matsuura12Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206Department of Cell Chemistry, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine and Dentistry, Okayama 700-8558, Japan; Department of Immunochemistry, Faculty of Pharmaceutical Science, Okayama University, Okayama 700-8530, Japan; Department of Medicine II, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan; Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital London, SE1 7EH, UK; Division of Bioscience, Graduate School of Environment Earth Science, Hokkaido University, Sapporo 060-0810, Japan; Program in Cell Biology, Department of Medicine, National Jewish Medical and Research Center, Denver, CO 80206β2-glycoprotein I (β2-GPI) is a major antigen for antiphospholipid antibodies (Abs, aPL) present in patients with antiphospholipid syndrome (APS). We recently reported (J. Lipid Res., 42: 697, 2001; J. Lipid Res., 43: 1486, 2002) that β2-GPI specifically binds to Cu2+-oxidized LDL (oxLDL) and that the β2-GPI ligands are ω-carboxylated 7-ketocholesteryl esters. In the present study, we demonstrate that oxLDL forms stable and nondissociable complexes with β2-GPI in serum, and that high serum levels of the complexes are associated with arterial thrombosis in APS. A conjugated ketone function at the 7-position of cholesterol as well as the ω-carboxyl function of the β2-GPI ligands was necessary for β2-GPI binding. The ligand-mediated noncovalent interaction of β2-GPI and oxLDL undergoes a temperature- and time-dependent conversion to much more stable but readily dissociable complexes in vitro at neutral pH. In contrast, stable and nondissociable β2-GPI-oxLDL complexes were frequently detected in sera from patients with APS and/or systemic lupus erythematodes. Both the presence of β2-GPI-oxLDL complexes and IgG Abs recognizing these complexes were strongly associated with arterial thrombosis. Further, these same Abs correlated with IgG immune complexes containing β2-GPI or LDL.Thus, the β2-GPI-oxLDL complexes acting as an autoantigen are closely associated with autoimmune-mediated atherogenesis.http://www.sciencedirect.com/science/article/pii/S0022227520311615antiphospholipid syndromearterial thrombosisautoantibody